Bathje, G. J., Majeski, E., & Kudowor, M. (2022). Psychedelic integration: An analysis of the concept and its practice. Frontiers in Psychology, 13, 824077. https://doi.org/10.3389/fpsyg.2022.824077

​

Calder, A. E., & Hasler, G. (2023). Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology, 48(1), 104–112. https://doi.org/10.1038/s41386-022-01389-z

​

Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994

​

Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., Hobden, P., Evans, J., Feilding, A., Wise, R. G., & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138–2143. https://doi.org/10.1073/pnas.1119598109

​

Castro Santos, H., & Gama Marques, J. (2021). What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review. Porto Biomedical Journal, 6(1), e128. https://doi.org/10.1097/j.pbj.0000000000000128

​

Chopra, S., & Letheby, C. (2024). Psychedelics and moral psychology: The case of forgiveness. In C. Letheby & P. Gerrans (Eds.), Philosophical Perspectives on Psychedelic Psychiatry (1st ed., pp. 211–232). Oxford University PressOxford. https://doi.org/10.1093/oso/9780192898371.003.0010

​

Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., Smith, G. S., Pekar, J. J., Barker, P. B., Griffiths, R. R., & Barrett, F. S. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational Psychiatry, 11(1), 574. https://doi.org/10.1038/s41398-021-01706-y

​

Freitas, R. R., Gotsis, E. S., Gallo, A. T., Fitzgibbon, B. M., Bailey, N. W., & Fitzgerald, P. B. (2025). The safety of psilocybin-assisted psychotherapy: A systematic review. Australian & New Zealand Journal of Psychiatry, 59(2), 128–151. https://doi.org/10.1177/00048674241289024

​

Garcia-Romeu, A., Barrett, F. S., Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R. (2021). Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. Journal of Psychopharmacology, 35(4), 353–361. https://doi.org/10.1177/0269881121991822

​

Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6), 621–632. https://doi.org/10.1177/0269881108094300

​

Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (n.d.). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.

​

Haikazian, S., Chen-Li, D. C. J., Johnson, D. E., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2023a). Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry Research, 329, 115531. https://doi.org/10.1016/j.psychres.2023.115531

​

Jones, J. L. (2025). Harnessing neuroplasticity with psychoplastogens: The essential role of psychotherapy in psychedelic treatment optimization. Frontiers in Psychiatry, 16, 1565852. https://doi.org/10.3389/fpsyt.2025.1565852

​

Li, N.-X., Hu, Y.-R., Chen, W.-N., & Zhang, B. (2022). Dose effect of psilocybin on primary and secondary depression: A preliminary systematic review and meta-analysis. Journal of Affective Disorders, 296, 26–34. https://doi.org/10.1016/j.jad.2021.09.041

​

Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L. (2021). The Therapeutic Potential of Psilocybin. Molecules, 26(10), 2948. https://doi.org/10.3390/molecules26102948

​

Neitzke-Spruill, L., Beit, C., Robinson, J., Blevins, K., Reynolds, J., Evans, N. G., & McGuire, A. L. (2024). A Transformative Trip? Experiences of Psychedelic Use. Neuroethics, 17(2), 33. https://doi.org/10.1007/s12152-024-09567-0

​

Olson, D. E. (2022). Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity. Biochemistry, 61(3), 127–136. https://doi.org/10.1021/acs.biochem.1c00812

​

Perez, N., Langlest, F., Mallet, L., De Pieri, M., Sentissi, O., Thorens, G., Seragnoli, F., Zullino, D., Kirschner, M., Kaiser, S., Solmi, M., & Sabé, M. (2023). Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. European Neuropsychopharmacology, 76, 61–76. https://doi.org/10.1016/j.euroneuro.2023.07.011

​

Virtue Recovery Center. (2025, May 13). Psilocybin vs Psilocin: Differences in Magic Mushrooms? https://www.virtuerecoverycenter.com/psilocybin-vs-psilocin/

​

Yockey, A., & King, K. (2021). Use of psilocybin (“mushrooms”) among US adults: 2015–2018. Journal of Psychedelic Studies, 5(1), 17–21. https://doi.org/10.1556/2054.2020.00159